Gibson Oncology, LLC

Gibson Oncology is a biotechnology startup founded in 2018 with a focus on developing a novel class of proprietary drug candidates aimed at treating difficult-to-treat tumors. The company's slogan, "Tough on cancer. Not on Patients.", reflects its commitment to innovative, patient-centered treatment approaches.

Their product candidates are distinguished by their first-in-class dual activity at C-MYC and Topo-1, which is expected to enhance both safety and efficacy. This groundbreaking approach holds the potential to revolutionize the treatment landscape for several types of cancers. Notably, there are currently five (5) ongoing clinical studies funded by the National Institutes of Health in patients with solid tumors and lymphomas, underscoring the scientific and medical community's interest and support for Gibson Oncology's endeavors.

Furthermore, the company has developed proprietary second-generation product candidates that expand modes of delivery and treatment approaches, with a specific focus on both pediatric and adult populations. This highlights their dedication to addressing unmet medical needs across diverse patient demographics.

Gibson Oncology operates within the Biotechnology and Health Care industries, positioning itself at the intersection of cutting-edge science and healthcare innovation. As they continue to advance their drug candidates through clinical trials, the startup presents an intriguing opportunity for investors in the biotech space, with the potential for significant impact in the fight against cancer.

With its pioneering approach, compelling clinical data, and commitment to enhancing patient outcomes, Gibson Oncology stands as an attractive prospect for venture capital firms seeking to contribute to groundbreaking advancements in oncology and biopharmaceuticals.